About Sudeep Pharma Limited
Data last updated: 06 January 2026
Sudeep Pharma Limited is a public limited company based in Baroda, Gujarat, India. It specialises in preventive health supplements, a part of the broader healthcare sector. Incorporated on 21 December 1989, the company has been in operation for over 37 years.
Registered with ROC Ahmedabad under CIN L24231GJ1989PLC013141.
Capital: an authorised share capital of ₹15 Cr and a paid-up capital of ₹11.29 Cr. Formerly known as Sudeep Pharma Limited. It is led by directors including Reshma Suresh Patel and Raghunandan Sathyanarayan Rao.
Last AGM: 28 August 2025. Financial statements filed for year ended 31 March 2025. Office: 129/1/A G.I.D.C. Estate Nandesari, Baroda, Gujarat, India – 391340.
As per the financials filed for FY 2025, the company reported a revenue of ₹511.33 Cr, a growth of 10% compared to the previous year.
The company has a workforce of approximately 377 employees as per the latest available data.
The company is associated with 2 brands - Sudeep Pharma, Sudeep Pharma. As per MCA filings, the company has open charges of ₹146.5 Cr and satisfied charges of ₹81.9 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website sudeepgroup.com.
-
Email**************
-
Telephone**************
-
Website**************
-
Social Media**************
-
Registered Address129/1/A G.I.D.C. Estate Nandesari, Baroda, Gujarat, India – 391340
-
IndustryHealthcare, Preventive Health Supplements
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
CIN History of Sudeep Pharma Limited
Sudeep Pharma Limited has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L24231GJ1989PLC013141, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L24231GJ1989PLC013141 | Current |
| U24231GJ1989PLC013141 | Previous |
| U24231GJ1989PTC013141 | Previous |
Associated Brands with Sudeep Pharma Limited
Sudeep Pharma Limited operates two associated brands: Sudeep Pharma and Sudeep Pharma. These brands represent Sudeep Pharma Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Pharmaceutical excipients and ingredients are manufactured for multiple industries. | sudeeppharma.com | |
| Sudeep Pharma is involved in pharmaceutical and nutrition sectors. | sudeepgroup.com |
Competitors & Alternatives of Sudeep Pharma Limited
Brands and companies operating in the same space as Sudeep Pharma Limited include Colorcon, DFE Pharma, Crest Cellulose and 7 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
Colorcon
|
Developer of specialty excipients and corporate-backed venture capital fund focused on healthcare startups | Harleysville, United States, United States | 1961 |
DFE Pharma
|
Developer and manufacturer of excipients for oral solid dosage forms and dry powder inhalations | Goch, Germany, Germany | 2011 |
Crest Cellulose
|
Pharmaceutical excipients and food ingredients are developed and manufactured. | Hyderabad, India, India | 2011 |
Scope Ingredients
|
Formulations, warehousing, and logistics services for pharmaceuticals are provided. | Chennai, India, India | 1959 |
Pfanstiehl
|
APIs, injectable excipients, and bioprocessing solutions are manufactured. | Waukegan, United States, United States | 1919 |
Vikram Thermo
|
Manufacturer of excipients for small molecules | Ahmedabad, India, India | 1984 |
SPI Pharma
|
Excipient products and formulations are manufactured for pharmaceutical uses. | Wilmington, United States, United States | 2000 |
Meggle Pharma
|
Develops and manufactures pharmaceutical excipients for the industry. | Wasserburg Am Inn, Germany, Germany | 2005 |
JRS Pharma
|
Supplies excipients, coatings, and technical services for health sciences worldwide. | Baden Baden, Germany, Germany | 1878 |
Boai Nky Pharmaceuticals
|
Develops and manufactures pharmaceutical excipients, specializing in PVP products. | Jiaozuo, China, China | 1987 |
Business Activity of Sudeep Pharma Limited
Sudeep Pharma Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | ********* |
Auditor Details of Sudeep Pharma Limited
Sudeep Pharma Limited is audited by B S R and Co., (ICAI peer reviewed, certificate valid till 2029-04-30) for the financial year 2026, as reported in its NSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.
| Name | Financial year | Audit opinion |
|---|---|---|
| B S R and Co., (ICAI peer reviewed, certificate valid till 2029-04-30) | FY 2026 | Declaration of unmodified opinion |
Board of Directors of Sudeep Pharma Limited
Sudeep Pharma Limited is currently managed by 9 directors, with 20 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
Financials of Sudeep Pharma Limited FY 2026 filings available
Sudeep Pharma Limited reported revenue of ₹642.26 Cr (up ) for FY 2026. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | FY 2026 |
|---|---|
| Revenue from Operations | ₹642.26 Cr |
| Other Income | ₹28.59 Cr |
| Total Income | ₹670.84 Cr |
| Cost of Materials Consumed | ₹269.5 Cr |
| Purchases of Stock-in-Trade | ₹0 |
| Changes in Inventories | -₹42.2 Cr |
| Employee Benefit Expense | ₹51.89 Cr |
| Finance Costs | ₹7.6 Cr |
| Depreciation & Amortisation | ₹14.81 Cr |
| Other Expenses | ₹141.16 Cr |
| Total Expenses | ₹442.77 Cr |
| Profit Before Exceptional Items & Tax | ₹228.07 Cr |
| Exceptional Items | ₹0 |
| Profit Before Tax | ₹228.07 Cr |
| Total Tax Expense | ₹53.79 Cr |
| Net Profit | ₹174.28 Cr |
| attributable to Owners | ₹172.89 Cr |
| attributable to NCI | ₹1.39 Cr |
| Other Comprehensive Income | -₹1.23 Cr |
| Total Comprehensive Income | ₹173.06 Cr |
| EBITDA (computed) | ₹250.49 Cr |
| Basic EPS | ₹15.50 |
| Diluted EPS | ₹15.50 |
| Metrics | FY 2026 |
|---|---|
| Total Assets | ₹1,174.88 Cr |
| Non-current Assets | ₹550.91 Cr |
| Current Assets | ₹623.97 Cr |
| Property, Plant & Equipment | ₹224 Cr |
| Inventories | ₹216.05 Cr |
| Trade Receivables | ₹227.54 Cr |
| Cash & Equivalents | ₹26.74 Cr |
| Equity (Net Worth) | ₹898.09 Cr |
| Equity Share Capital | ₹11.29 Cr |
| Borrowings (Non-current) | ₹34.29 Cr |
| Borrowings (Current) | ₹114 Cr |
| Total Debt (computed) | ₹148.29 Cr |
| Current Liabilities | ₹201.96 Cr |
| Total Liabilities | ₹276.78 Cr |
| Metrics | FY 2026 |
|---|---|
| Operating Cash Flow | ₹69.55 Cr |
| Investing Cash Flow | -₹327.19 Cr |
| Financing Cash Flow | ₹247.29 Cr |
| Capital Expenditure | ₹118.15 Cr |
| Free Cash Flow (computed) | -₹48.6 Cr |
| Dividends Paid | ₹0 |
| Net Change in Cash | -₹10.07 Cr |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 |
|---|---|---|---|
| Revenue from Operations | ₹182.34 Cr | ₹172.34 Cr | ₹162.67 Cr |
| Other Income | ₹6.42 Cr | ₹6.84 Cr | ₹10.17 Cr |
| Total Income | ₹188.76 Cr | ₹179.17 Cr | ₹172.83 Cr |
| Cost of Materials Consumed | ₹71.14 Cr | ₹70.26 Cr | ₹70.48 Cr |
| Purchases of Stock-in-Trade | ₹0 | ₹0 | ₹0 |
| Changes in Inventories | -₹7.28 Cr | -₹10.07 Cr | -₹9.54 Cr |
| Employee Benefit Expense | ₹10.52 Cr | ₹15.04 Cr | ₹14.1 Cr |
| Finance Costs | ₹2.44 Cr | ₹1.17 Cr | ₹2.28 Cr |
| Depreciation & Amortisation | ₹3.88 Cr | ₹3.86 Cr | ₹3.81 Cr |
| Other Expenses | ₹45.37 Cr | ₹37.13 Cr | ₹32.17 Cr |
| Total Expenses | ₹126.07 Cr | ₹117.4 Cr | ₹113.3 Cr |
| Profit Before Exceptional Items & Tax | ₹62.69 Cr | ₹61.78 Cr | ₹59.53 Cr |
| Exceptional Items | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹62.69 Cr | ₹61.78 Cr | ₹59.53 Cr |
| Total Tax Expense | ₹14.15 Cr | ₹14.08 Cr | ₹12.76 Cr |
| Net Profit | ₹48.54 Cr | ₹47.7 Cr | ₹46.78 Cr |
| attributable to Owners | ₹48.88 Cr | -₹2.03 Cr | ₹45.75 Cr |
| attributable to NCI | -₹33.84 Lakh | ₹6.16 Lakh | ₹1.03 Cr |
| Other Comprehensive Income | ₹6.16 Cr | -₹1.97 Cr | -₹2.58 Cr |
| Total Comprehensive Income | ₹54.7 Cr | ₹45.73 Cr | ₹44.19 Cr |
| EBITDA (computed) | ₹69.02 Cr | ₹66.81 Cr | ₹65.63 Cr |
| Basic EPS | ₹4.38 | ₹4.29 | ₹4.20 |
| Diluted EPS | ₹4.38 | ₹4.29 | ₹4.20 |
| Segment · Q4 FY26 (latest quarter) | Revenue | Result (PBIT) | Assets | Liabilities |
|---|---|---|---|---|
| Pharmaceutical, Food and Nutrition | ₹90.1 Cr | ₹27.6 Cr | ₹727.21 Cr | ₹217.88 Cr |
| Speciality Ingredients | ₹92.24 Cr | ₹31.11 Cr | ₹443.74 Cr | ₹48.51 Cr |
| Inter Segment Revenue | ₹3 Cr | ₹0 | ₹0 | ₹0 |
| Segment · FY 2026 (annual) | Revenue | Result (PBIT) | Assets | Liabilities |
|---|---|---|---|---|
| Pharmaceutical, Food and Nutrition | ₹362.64 Cr | ₹113.52 Cr | - | - |
| Speciality Ingredients | ₹279.62 Cr | ₹93.58 Cr | - | - |
| Inter Segment Revenue | ₹8.47 Cr | ₹0 | - | - |
| Metrics | FY 2026 |
|---|---|
| Revenue from Operations | ₹338.51 Cr |
| Other Income | ₹38.5 Cr |
| Total Income | ₹377.01 Cr |
| Cost of Materials Consumed | ₹156.84 Cr |
| Purchases of Stock-in-Trade | ₹0 |
| Changes in Inventories | -₹45.5 Cr |
| Employee Benefit Expense | ₹28.95 Cr |
| Finance Costs | ₹6.07 Cr |
| Depreciation & Amortisation | ₹7.11 Cr |
| Other Expenses | ₹78.45 Cr |
| Total Expenses | ₹231.91 Cr |
| Profit Before Exceptional Items & Tax | ₹145.1 Cr |
| Exceptional Items | ₹0 |
| Profit Before Tax | ₹145.1 Cr |
| Total Tax Expense | ₹37.52 Cr |
| Net Profit | ₹107.58 Cr |
| Other Comprehensive Income | -₹2.65 Lakh |
| Total Comprehensive Income | ₹107.55 Cr |
| EBITDA (computed) | ₹158.27 Cr |
| Basic EPS | ₹9.65 |
| Diluted EPS | ₹9.65 |
| Metrics | FY 2026 |
|---|---|
| Total Assets | ₹973.78 Cr |
| Non-current Assets | ₹515.83 Cr |
| Current Assets | ₹457.95 Cr |
| Property, Plant & Equipment | ₹90.27 Cr |
| Inventories | ₹130.77 Cr |
| Trade Receivables | ₹80.13 Cr |
| Cash & Equivalents | ₹2.18 Cr |
| Equity (Net Worth) | ₹786.01 Cr |
| Equity Share Capital | ₹11.29 Cr |
| Borrowings (Non-current) | ₹34.29 Cr |
| Borrowings (Current) | ₹90.65 Cr |
| Total Debt (computed) | ₹124.93 Cr |
| Current Liabilities | ₹145.07 Cr |
| Total Liabilities | ₹187.77 Cr |
| Metrics | FY 2026 |
|---|---|
| Operating Cash Flow | ₹96.02 Cr |
| Investing Cash Flow | -₹366.68 Cr |
| Financing Cash Flow | ₹242.5 Cr |
| Capital Expenditure | ₹63.33 Cr |
| Free Cash Flow (computed) | ₹32.68 Cr |
| Dividends Paid | ₹0 |
| Net Change in Cash | -₹28.16 Cr |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 |
|---|---|---|---|
| Revenue from Operations | ₹80.17 Cr | ₹90.28 Cr | ₹87.88 Cr |
| Other Income | ₹9.62 Cr | ₹9.44 Cr | ₹12.83 Cr |
| Total Income | ₹89.79 Cr | ₹99.72 Cr | ₹100.71 Cr |
| Cost of Materials Consumed | ₹37.86 Cr | ₹41.73 Cr | ₹44.41 Cr |
| Purchases of Stock-in-Trade | ₹0 | ₹0 | ₹0 |
| Changes in Inventories | -₹16.89 Cr | -₹10.87 Cr | -₹11.34 Cr |
| Employee Benefit Expense | ₹5.99 Cr | ₹8.15 Cr | ₹7.42 Cr |
| Finance Costs | ₹1.97 Cr | ₹63.2 Lakh | ₹2.03 Cr |
| Depreciation & Amortisation | ₹1.79 Cr | ₹1.79 Cr | ₹1.77 Cr |
| Other Expenses | ₹24.32 Cr | ₹21.65 Cr | ₹16.52 Cr |
| Total Expenses | ₹55.04 Cr | ₹63.1 Cr | ₹60.81 Cr |
| Profit Before Exceptional Items & Tax | ₹34.74 Cr | ₹36.62 Cr | ₹39.9 Cr |
| Exceptional Items | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹34.74 Cr | ₹36.62 Cr | ₹39.9 Cr |
| Total Tax Expense | ₹8.98 Cr | ₹9.76 Cr | ₹10.16 Cr |
| Net Profit | ₹25.77 Cr | ₹26.87 Cr | ₹29.74 Cr |
| Other Comprehensive Income | ₹15.25 Lakh | -₹24.85 Lakh | ₹5.9 Lakh |
| Total Comprehensive Income | ₹25.92 Cr | ₹26.62 Cr | ₹29.8 Cr |
| EBITDA (computed) | ₹38.5 Cr | ₹39.05 Cr | ₹43.71 Cr |
| Basic EPS | ₹2.31 | ₹2.42 | ₹2.67 |
| Diluted EPS | ₹2.31 | ₹2.42 | ₹2.67 |
Board & Governance of Sudeep Pharma Limited
As per the corporate governance filing with NSE for the quarter ended 31-MAR-2026, the board of Sudeep Pharma Limited has 7 directors - 4 independent and 3 executive. The board is chaired by BHAYANI SUJIT JAYSUKH.
| Director | Position | On board since | Listed boards |
|---|---|---|---|
| SHANIL SUJIT BHAYANI | Executive Director | 2021-12-10 | 1 |
| BHAYANI SUJIT JAYSUKH | Executive Director · Chairperson | 1995-03-01 | 1 |
| AJAY SHRIRANG KANDELKAR | Executive Director | 2024-09-13 | 1 |
| SAMARESH PARIDA | Non-Executive - Independent Director | 2024-09-13 | 3 |
| RAGHUNANDAN SATHYANARAYAN RAO | Non-Executive - Independent Director | 2024-09-13 | 1 |
| RESHMA SURESH PATEL | Non-Executive - Independent Director | 2024-09-13 | 2 |
| SUJIT GULATI | Non-Executive - Independent Director | 2024-09-13 | 3 |
| Committee | Members |
|---|---|
| Audit Committee | SAMARESH PARIDA (Chairperson), RESHMA SURESH PATEL, SUJIT JAYSUKH BHAYANI |
| Nomination and remuneration committee | RESHMA SURESH PATEL (Chairperson), SAMARESH PARIDA, SUJIT GULATI |
| Stakeholders Relationship Committee | SUJIT GULATI (Chairperson), RAGHUNANDAN SATHYANARAYAN RAO, SUJIT JAYSUKH BHAYANI, SHANIL SUJIT BHAYANI |
| Risk Management Committee | RAGHUNANDAN SATHYANARAYAN RAO (Chairperson), SUJIT JAYSUKH BHAYANI, SHANIL SUJIT BHAYANI, SUJIT GULATI |
| Corporate Social Responsibility Committee | SUJIT JAYSUKH BHAYANI (Chairperson), SHANIL SUJIT BHAYANI, RESHMA SURESH PATEL |
| IPO Committee | SUJIT JAYSUKH BHAYANI (Chairperson), SHANIL SUJIT BHAYANI, SAMARESH PARIDA |
Charges & Borrowings of Sudeep Pharma Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 30 Dec 2024 | Others | ₹75 Cr | Open |
| 29 Sep 2020 | Citi Bank N.A. | ₹20 Cr | Open |
| 20 Aug 2019 | Citi Bank N.A. | ₹6.5 Cr | Open |
| 27 Jan 2014 | Citi Bank N.A. | ₹45 Cr | Open |
| 29 Jan 2022 | Others | ₹60.69 Cr | Satisfied |
Total charge records: 17 View all charges
Employees and EPFO Compliance at Sudeep Pharma Limited
View historical data on people associated with Sudeep Pharma Limited, including employment history and EPFO contributions.
Employee Count & EPFO Data of Sudeep Pharma Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Sudeep Pharma Limited
GSTIN & GST Filing Data of Sudeep Pharma Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Sudeep Pharma Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Sudeep Pharma Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Sudeep Pharma Limited
MSME Payment Delays by Sudeep Pharma Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Sudeep Pharma Limited
Subsidiaries & Group Companies of Sudeep Pharma Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Sudeep Pharma Limited with ownership details.
MCA Filings & Documents of Sudeep Pharma Limited
MCA Filings & Documents of Sudeep Pharma Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Sudeep Pharma Limited
Frequently Asked Questions about Sudeep Pharma Limited
Sudeep Pharma Limited is an active public limited company in the healthcare sector based in Baroda, Gujarat, India. It was incorporated on 21 December 1989 (37+ years old) and is registered under CIN L24231GJ1989PLC013141. The company has 377 employees.
Sudeep Pharma Limited reported revenue of ₹511.33 Cr for FY 2025 (up 10.00% YoY).
The current directors of Sudeep Pharma Limited are:
- Reshma Suresh Patel
- Raghunandan Sathyanarayan Rao
- Sujit Jaysukh Bhayani
- Ajay Shrirang Kandelkar
- Shanil Sujit Bhayani
- Samaresh Parida
- Sujit Gulati
- Ketan Jagdishchandra Vyas
- Dimple Ashwinbhai Mehta
The primary industry of Sudeep Pharma Limited is healthcare. The company specifically operates in preventive health supplements. The company is currently active in this sector.
Sudeep Pharma Limited can be reached at the registered office: 1291A G.I.D.C. Estate Nandesari, Baroda, Gujarat, India – 391340, or through the website sudeepgroup.com.
The authorised capital is ₹15 Cr, and the paid-up capital is ₹11.29 Cr.